Abbott Laboratories $ABT Shares Sold by Dai ichi Life Insurance Company Ltd

Dai ichi Life Insurance Company Ltd lowered its stake in shares of Abbott Laboratories (NYSE:ABT) by 5.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 117,202 shares of the healthcare product maker’s stock after selling 6,470 shares during the quarter. Dai ichi Life Insurance Company Ltd’s holdings in Abbott Laboratories were worth $12,033,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ABT. Brighton Jones LLC increased its holdings in Abbott Laboratories by 10.1% during the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after purchasing an additional 4,755 shares during the period. Sivia Capital Partners LLC boosted its stake in shares of Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after buying an additional 162 shares during the period. United Bank grew its position in shares of Abbott Laboratories by 7.4% during the second quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock worth $3,945,000 after buying an additional 2,001 shares in the last quarter. Main Street Financial Solutions LLC increased its stake in shares of Abbott Laboratories by 13.6% during the second quarter. Main Street Financial Solutions LLC now owns 11,894 shares of the healthcare product maker’s stock worth $1,618,000 after buying an additional 1,428 shares during the period. Finally, Canada Pension Plan Investment Board raised its holdings in Abbott Laboratories by 25.6% in the second quarter. Canada Pension Plan Investment Board now owns 1,435,683 shares of the healthcare product maker’s stock valued at $195,267,000 after acquiring an additional 292,547 shares in the last quarter. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ABT has been the subject of several analyst reports. TD Cowen reiterated a “buy” rating and set a $115.00 price target on shares of Abbott Laboratories in a report on Friday, July 17th. Weiss Ratings lowered shares of Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday. Robert W. Baird initiated coverage on shares of Abbott Laboratories in a research report on Wednesday, July 1st. They set an “outperform” rating and a $121.00 price objective for the company. Jefferies Financial Group lowered their target price on shares of Abbott Laboratories from $145.00 to $135.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Finally, Sanford C. Bernstein cut their price target on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $118.61.

Insider Activity at Abbott Laboratories

In other news, Director Daniel J. Starks bought 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The stock was acquired at an average cost of $92.65 per share, with a total value of $926,500.00. Following the acquisition, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $103.13 on Friday. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $137.49. The firm’s 50 day moving average is $91.61 and its two-hundred day moving average is $101.33. The firm has a market capitalization of $179.63 billion, a P/E ratio of 33.38, a P/E/G ratio of 1.95 and a beta of 0.61.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.03. The business had revenue of $12.51 billion during the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.65%. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts forecast that Abbott Laboratories will post 5.51 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.